Low-Molecular Weight Caldesmon as a Potential Serum Marker for Glioma

Zheng, Peng; Hop, Wim C. J.; Smitt, Peter A.E. Sillevis; Bent, Martin J. van den; Avezaat, C. J. J.; Luider, Theodorus M.; Kros, Johan M.

doi:10.1158/1078-0432.ccr-04-2512

Cited by 46 publications

(29 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4,5 We also found that abnormal splicing results in the upregulation of the entire l-CaD class in glioma tissue samples 4 and body fluids. 6,7 We assumed that the abnormal expression of Hela l-CaD in neoplastic vasculature is implicated in tumor neovascularization.…”

Section: Introductionmentioning

confidence: 99%

Hela l-CaD Is Implicated in the Migration of Endothelial Cells/Endothelial Progenitor Cells in Human Neoplasms

Zheng

Weiden

Kros

2007

Cell Adhesion & Migration

Self Cite

View full text Add to dashboard Cite

Caldesmon (CaD) is a major actin-binding protein distributed in a variety of cell types. No functional differences among the isoforms in in vitro studies were found so far. In a previous study we found that the low molecular caldesmon isoform (Hela l-CaD) is expressed in endothelial cells (ECs)/endothelial progenitor cells (EPCs) in tumor vasculature of various human tumors. Activation of cell motility is necessary for the navigation of the tip ECs during angiogenesis, and migration of EPCs from the bone marrow during vasculogenesis. In the present study we searched for features of motility and the intracellular expression sites of Hela l-CaD in ECs/EPCs of various human tumors under histologically preserved microenviroment. We discovered a variety of motility-related cell protrusions like filopodia, microspikes, lamellipodia, podosomes, membrane blebs and membrane ruffles in the activated ECs/EPCs. Hela l-CaD appeared to be invariably expressed in the subregions of these cell protrusions. The findings suggest that Hela l-CaD is implicated in the migration of ECs/EPC in human neoplasms where they contribute to tumor vasculogenesis and angiogenesis.

show abstract

Section: Introductionmentioning

confidence: 99%

Hela l-CaD Is Implicated in the Migration of Endothelial Cells/Endothelial Progenitor Cells in Human Neoplasms

Zheng

Weiden

Kros

2007

Cell Adhesion & Migration

Self Cite

View full text Add to dashboard Cite

show abstract

“…5,6 No such blood markers have been identified for glioma patients, although a few candidate proteins (cathepsin D, low-molecular-weight caldesmon, YKL-40, matrix metalloproteinase-9, and glial fibrillary acidic protein) have been recently reported. [7][8][9][10] In this study, we tested the potential use of measuring plasma insulin-like growth factor binding protein 2 (IGFBP-2) levels in the setting of glioma.…”

mentioning

confidence: 99%

Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas

et al. 2009

View full text Add to dashboard Cite

Insulin-like growth factor binding protein 2 (IGFBP-2) is a malignancy-associated protein measurable in tumors and blood. Increased IGFBP-2 is associated with shortened survival of advanced glioma patients. Thus, we examined plasma IGFBP-2 levels in glioma patients and healthy controls to evaluate its value as a plasma biomarker for glioma. Plasma IGFBP-2 levels in 196 patients with newly diagnosed glioma and 55 healthy controls were analyzed using an IGFBP-2 ELISA kit. Blood was collected before surgery, after two-cycle adjuvant chemotherapy, and at recurrence. Plasma IGFBP-2 levels were correlated with disease-free survival (DFS) using Cox regression analyses. We found that preoperative plasma IGFBP-2 levels were significantly higher in high-grade glioma patients (n 5 43 for grade III glioma; n 5 72 for glioblastoma multiforme [GBM]) than in healthy controls (n 5 55; p , 0.001) and low-grade (grade II) glioma patients (n 5 81; p , 0.001). No significant differences in preoperative plasma IGFBP-2 levels were observed between grade III glioma and GBM patients or between grade II glioma patients and healthy controls. After recurrence, plasma IGFBP-2 levels were significantly increased in GBM patients (n 5 26; p , 0.001). Preoperative plasma IGFBP-2 levels were significantly correlated with DFS in GBM patients (hazard ratio, 1.404; 95% confidence interval, 1.078-1.828; p 5 0.012). We conclude that preoperative plasma IGFBP-2 levels are significantly higher in high-grade glioma patients than in low-grade glioma patients and healthy subjects, and are significantly correlated with recurrence and DFS in patients with GBM. Longitudinal studies with a larger study population are needed to confirm these findings.

show abstract

“…In other cancers, such as prostate cancer, serum tumor markers are used to diagnose malignancy, assess treatment response, and even predict survival. No such serum markers have been identified for brain tumors although ongoing research has identified potential candidate proteins (3,4).…”

mentioning

confidence: 99%

YKL-40 and Matrix Metalloproteinase-9 as Potential Serum Biomarkers for Patients with High-Grade Gliomas

Hormigo

Gu²,

Karimi

et al. 2006

Clinical Cancer Research

166

149

View full text Add to dashboard Cite

Purpose: Biomarkers can facilitate diagnosis, monitor treatment response, and assess prognosis in some patients with cancer. YKL-40 and matrix metalloproteinase-9 (MMP-9) are two proteins highly differentially expressed by malignant gliomas.We obtained prospective longitudinal serum samples from patients with gliomas to determine whether YKL-40 or MMP-9 could be used as serum markers. Experimental Design: Serum samples were obtained concurrently with magnetic resonance imaging scans. YKL-40 and MMP-9 were determined by ELISA and the values correlated with the patient's radiographic status and survival. Results: High-grade glioma patients who underwent a surgical resection of their tumor had transient increase of bothYKL-40 and MMP-9 serum levels in the postoperative period. Glioblastoma multiforme (GBM) patients with no radiographic evidence of disease (n = 10 patients, 50 samples) had a significantly lower level ofYKL-40 and MMP-9 than patients with active tumor (n = 66 patients, 209 samples; P = 0.0003 and 0.0002, respectively). Anaplastic glioma patients with no radiographic evidence of disease (n = 32 patients, 107 samples) also had a significantly lower level of YKL-40 compared with those patients with active tumor (n = 48 patients, 199 samples; P = 0.04). There was a significant inverse association between YKL-40 and survival in GBM, hazard ratio (hazard ratio, 1.4; P = 0.02), and anaplastic astrocytoma patients (hazard ratio, 2.2; P = 0.05). Conclusions: YKL-40 and MMP-9 can be monitored in patients' serum and help confirm the absence of active disease in GBM and YKL-40 in anaplastic glioma patients. YKL-40 can be used as predictor of survival in patients with high-grade glioma. Longitudinal studies with a larger patient population are needed to confirm these findings.

show abstract

Low-Molecular Weight Caldesmon as a Potential Serum Marker for Glioma

Cited by 46 publications

References 19 publications

Hela l-CaD Is Implicated in the Migration of Endothelial Cells/Endothelial Progenitor Cells in Human Neoplasms

Hela l-CaD Is Implicated in the Migration of Endothelial Cells/Endothelial Progenitor Cells in Human Neoplasms

Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas

YKL-40 and Matrix Metalloproteinase-9 as Potential Serum Biomarkers for Patients with High-Grade Gliomas

Contact Info

Product

Resources

About